

Study: Many Individuals Discover Too Late that They are Infected with Hepatitis B Virus; CBCD Comments on the Study


Patients with chronic hepatitis B who acquire the virus early in life will eventually develop serious health problems too late for treatment. (1)

ROCHESTER, NEW YORK, UNITED STATES, January 25, 2015 /EINPresswire.com/ --

"Infected with the hepatitis B virus (HBV)? The Center for the Biology of Chronic Disease (CBCD) recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD

A new study shows that people who become infected with the hepatitis B virus early in life can develop serious health problems. However, most infected people do not know that they have the virus. When they discover that they are infected, it is usually too late for effective treatment. The virus is an expert at hiding from the immune system in a latent (slightly dormant) state. When this happens, doctors say that a person has chronic hepatitis B (CHB). In fact, Dr. Revill and colleagues wrote in the study that "The HBV is regarded as a stealth virus, in part, due to its ability to subvert innate immune responses." (1) Dr. Revill is from the Victorian Infectious Diseases Reference Laboratory, in Melbourne, Australia. Because the HBV is able to hide from the immune system effectively. it can continue to replicate and produce viral proteins (although on a reduced scale) that nevertheless damage the body. "The adverse consequences of





CHB are due primarily to an inadequate and/or inappropriate host immune response. "(1) The Center for the Biology of Chronic Disease (CBCD) recommends that infected individuals take Novirin or Gene-Eden-VIR to help the immune system target the latent HBV.

clinical studies that followed FDA guidelines. The studies showed that the Novirin and Gene-Eden-VIR formula is effective against the HBV, and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, "individuals infected with the (hepatitis B and other viruses)...reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR." (2) The study authors also wrote that, "We observed a statistically significant decrease in the severity, duration, and frequency of symptoms." (2)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites.

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Gene-Eden-VIR and Novirin are the only natural antiviral products on the market with published clinical studies that support their claims.

In addition to the risks of a latent HBV infection, there is the issue of reactivation. Whenever the immune system is weakened, the virus can spontaneously reactivate. When that happens, problems that usually take a long time to develop suddenly become a reality. As another study points out "Reactivation of a former hepatitis B virus (HBV) infection can be triggered by immunosuppressive therapy, diseases associated with an immunocompromised state, organ transplantation or the withdrawal of antiviral drugs ... (and) ... aging, surgical stress and complication of disease(s) associated with compromised immunity, such as cancer, arteriosclerosis and diabetes mellitus may trigger spontaneous HBV reactivation." (See the Journal of Medical Virology, from January 21, 2015) (3)

According to the World Health Organization, "Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. It is a major global health problem. It can cause chronic liver disease and chronic infection and puts people at high risk of death from cirrhosis of the liver and liver cancer. More than 240 million people have chronic (long-term) liver infections. More than 780,000 people die every year due to the acute or chronic consequences of hepatitis B." (See the World Health Organization, last updated on July 2014) (4)

In many cases, there are no symptoms to let an individual know that he or she is infected. However, when symptoms do occur, they "appear 90 days (or 3 months) after exposure, but they can appear any time between 6 weeks and 6 months after exposure." (See the CDC, from June 9, 2009) (4) They can include "fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, clay-colored bowel movements, joint pain, and jaundice (yellow color in the skin or the eyes)." (5)

"Based on the above information, we recommend that HBV infected individuals take Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD

All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) Peter Revill, Stephen Locarnini "Viral factors and predicting disease outcomes in chronic hepatitis B."Gut 2015;64:191-193 doi:10.1136/gutjnl-2014-307398

http://gut.bmj.com/content/64/2/191.full

(2) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.

http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.U-s9ouOSz90

- (3) Kamitsukasa H1, Iri M, Tanaka A, Nagashima S, Takahashi M, Nishizawa T, Okamoto H. "Spontaneous reactivation of hepatitis B virus (HBV) infection in patients with resolved or occult HBV infection." J Med Virol. 2015 Jan 21. doi: 10.1002/jmv.24115. http://www.ncbi.nlm.nih.gov/pubmed/25612181
- (4) Who.int Hepatitis B. Updated July 2014. who.int/mediacentre/factsheets/fs204/en/
- (5) CDC Hepatitis B Information for the Public Hepatitis B FAQs for the Public. June 9, 2009. cdc.gov/hepatitis/b/bFAQ.htm#overview

Hanan Polansky Lilac Corp. 5852509999 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2015 IPD Group, Inc. All Right Reserved.